News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ProtAb, a Wholly Owned Subsidiary of Hadasit Bio Holdings, Receives U.S. Patent for Proximab for the Treatment of RA and Type-1 Diabetes



12/2/2008 9:49:38 AM

EIN KEREM, Israel--(BUSINESS WIRE)--ProtAb Ltd., a wholly owned subsidiary of Hadasit Bio-Holdings (TASE:HDST), announced today the receipt of an allowance of a key patent underlying its technology, an antibody called Proximab. The patent covers its structure as well as its immune and therapeutic activity against rheumatoid arthritis and Type-1 diabetes. Proximab is the basis for what will be the company’s flagship product. The company currently has a wide estate of patents registered in the United States, Australia, and European countries.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES